Group 1 - The core viewpoint of the article highlights the significant stock price increase of Bolekang Shiyun-B (02592), which rose over 4% during trading and has accumulated a gain of over 80% in the past week [1] - As of the report, the stock price is at 8.72 HKD with a trading volume of 6.7514 million HKD [1] - The company announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has successfully applied for patents in Japan and Europe for its core product CBT-009, marking an important milestone in its development process [1] Group 2 - The successful patent applications are expected to enhance the global coverage of CBT-009 and facilitate its commercialization [1] - The company anticipates establishing licensing arrangements with major pharmaceutical companies for the production, development, and distribution of CBT-009 in Japan and Europe, which are key high-end markets [1] - These collaborations and licensing agreements are expected to boost and accelerate the global commercialization potential of CBT-009 [1]
港股异动 | 拨康视云-B(02592)盘中涨超4% 近一周累计涨幅逾八成 公司将加速CBT-009全球商业化潜力